Catalog Number: 0949
Chemical Name: (-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol
Biological Activity
Cannabinoid agonist which is considerably more potent than Δ9-THC in both behavioral tests and receptor binding assays. Displays high and roughly equal affinity for both central and peripheral cannabinoid receptors (Ki = 0.6 - 5.0 and 0.7 - 2.6 nM at CB1 and CB2 respectively; EC50 values are 0.2, 0.3 and 5 nM at CB1, CB2 and GRP55 respectively).
Technical Data
  • M.Wt:
  • Formula:
  • Solubility:
    Soluble to 100 mM in ethanol and to 100 mM in DMSO
  • Purity:
  • Storage:
    Store at -20°C
  • CAS No:
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis. All Tocris products are intended for laboratory research use only.
Additional Information
Licensing Caveats:
Sold for research purposes under agreement from Pfizer Inc.

The citations listed below are publications that use Tocris products. Selected citations for CP 55,940 include:

Showing Results 1 - 10 of 35

  1. (4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs.
    Authors: Mahmoud Et al.
    Mol Pharmacol
  2. Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.
    Authors: Presley Et al.
    Eur J Pharmacol
  3. Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Authors: Mounsey Et al.
    Pharmacol Res Perspect
  4. Flavanones from Miconia prasina.
    Authors: Tarawneh Et al.
    Phytochem Lett
  5. Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: a Bayesian network analysis of data from a tissue microarray.
    Authors: Häggström Et al.
    J Biol Chem
  6. The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.
    Authors: Hruba and McMahon
    Br J Pharmacol
  7. Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a.
    Authors: Thomazeau Et al.
    J Neurosci
  8. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.
    Authors: Baillie Et al.
    Mol Pharmacol
  9. Long-term CB1 receptor blockade enhances vulnerability to anxiogenic-like effects of cannabinoids.
    Authors: Tambaro Et al.
  10. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.
    Authors: Prather Et al.
    Biochem Biophys Res Commun
  11. Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia.
    Authors: Seillier Et al.
    Eur J Pharmacol
  12. Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2.
    Authors: Marcu Et al.
    J Pharmacol Exp Ther
  13. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
    Authors: Rajasekaran Et al.
    Toxicol Appl Pharmacol
  14. Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.
    Authors: Marini Et al.
    Br J Pharmacol
  15. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.
    Authors: Brents Et al.
    Biochem Pharmacol
  16. CB1 receptor autoradiographic characterization of the individual differences in approach and avoidance motivation.
    Authors: Laricchiuta Et al.
    PLoS One
  17. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
    Authors: Chimalakonda Et al.
    Drug Metab Dispos
  18. AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.
    Authors: Bolognini Et al.
    Br J Pharmacol
  19. A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury.
    Authors: Horváth Et al.
    J Physiol
  20. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.
    Authors: Brents Et al.
    PLoS One
  21. Convulsant doses of a dopamine D1 receptor agonist result in Erk-dependent increases in Zif268 and Arc/Arg3.1 expression in mouse dentate gyrus.
    Authors: Gangarossa Et al.
    PLoS One
  22. Cannabinoids attenuate hippocampal γ oscillations by suppressing excitatory synaptic input onto CA3 pyramidal neurons and fast spiking basket cells.
    Authors: Holderith Et al.
    Br J Pharmacol
  23. Symptom-relieving and neuroprotective effects of the phytocannabinoid △9-THCV in animal models of Parkinson's disease.
    Authors: García Et al.
    J Cell Mol Med
  24. A putative 'pre-nervous' endocannabinoid system in early echinoderm development.
    Authors: Buznikov Et al.
    J Biol Chem
  25. Location, structure, and dynamics of the synthetic cannabinoid ligand CP-55,940 in lipid bilayers.
    Authors: Kimura Et al.
    Biophys J
  26. Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling.
    Authors: Georgieva Et al.
  27. Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction.
    Authors: Kapur Et al.
    J Pharmacol Exp Ther
  28. Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs.
    Authors: Giannini Et al.
  29. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
    Authors: Pertwee Et al.
    Br J Pharmacol
  30. S-nitrosothiols modulate G protein-coupled receptor signaling in a reversible and highly receptor-specific manner.
    Authors: Kokkola Et al.
    BMC Cell Biol
  31. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation.
    Authors: Ehrhart Et al.
    J Neuroinflammation
  32. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
    Authors: Thomas Et al.
    Br J Pharmacol
  33. Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor.
    Authors: Savinainen Et al.
    Br J Pharmacol
  34. Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716.
    Authors: Hilairet Et al.
    Exp Neurol
  35. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
    Authors: Savinainen Et al.
    Br J Pharmacol
Expand to show all
Tocris Bioscience is the leading supplier of novel and exclusive tools for life science research with over 30 years' experience in the industry. Tocris is a Bio-Techne brand.

Order Details


Contact Information

Molarity Calculator
Calculate the mass, volume or concentration required for a solution

The molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) x Volume (L) x Molecular Weight (g/mol)
An example of a molarity calculation using the molarity calculator:
What is the mass of compound required to make a 10 mM stock solution in 10 ml of water given that the molecular weight of the compound is 197.13 g/mol?

R&D Systems Guarantee

or select another batch:


Customer Information